UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors

Annals of oncology, 2024-02, Vol.35 (2), p.221-228

2024

Volltextzugriff (PDF)

GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer

Annals of oncology, 2018-11, Vol.29, p.ix86-ix86

2018

Volltextzugriff (PDF)

Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a phase I study

Annals of oncology, 2018-10, Vol.29, p.viii410-viii410

2018

Volltextzugriff (PDF)

Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data

Annals of oncology, 2018-10, Vol.29, p.viii461-viii462

2018

Volltextzugriff (PDF)

Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from phase I cohorts

Annals of oncology, 2018-10, Vol.29, p.viii342-viii343

2018

Volltextzugriff (PDF)

Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Annals of oncology, 2018-10, Vol.29, p.viii418-viii418

2018

Volltextzugriff (PDF)

Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)

Annals of oncology, 2018-10, Vol.29, p.viii414-viii414

2018

Volltextzugriff (PDF)

CLINICAL ACTIVITY OF REGN1979, AN ANTI‐CD20 X ANTI‐CD3 BISPECIFIC ANTIBODY (AB) IN PATIENTS (PTS) WITH (W/) RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL)

Hematological oncology, 2019-06, Vol.37 (S2), p.90-92

2019

Volltextzugriff (PDF)

Hormone replacement therapy, cancer, controversies, and women’s health: historical, epidemiological, biological, clinical, and advocacy perspectives

Journal of Epidemiology and Community Health, 2005-09, Vol.59 (9), p.740-748

2005

Volltextzugriff (PDF)

Risk factors for chronic and recurrent otitis media-a meta-analysis

PloS one, 2014-01, Vol.9 (1), p.e86397

2014

Volltextzugriff (PDF)

Alarming proportions of methicillin-resistant Staphylococcus aureus (MRSA) in wound samples from companion animals, Germany 2010-2012

PloS one, 2014-01, Vol.9 (1), p.e85656-e85656

2014

Volltextzugriff (PDF)

Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operons

PloS one, 2014-09, Vol.9 (9), p.e107426-e107426

2014

Volltextzugriff (PDF)

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma

The New England journal of medicine, 2022-10, Vol.387 (17), p.1557-1568

2022

Volltextzugriff (PDF)

Epidemiology and prognostic factors of candidemia in cancer patients

PloS one, 2014-06, Vol.9 (6), p.e99103-e99103

2014

Volltextzugriff (PDF)

Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma

Journal of immunotherapy, 2010-10, Vol.33 (8), p.828-833

2010

Volltextzugriff (PDF)

Lavage with allicin in combination with vancomycin inhibits biofilm formation by Staphylococcus epidermidis in a rabbit model of prosthetic joint infection

PloS one, 2014-07, Vol.9 (7), p.e102760-e102760

2014

Volltextzugriff (PDF)

Human Immunodeficiency Virus Type 1 Mutants Resistant to Nonnucleoside Inhibitors of Reverse Transcriptase Arise in Tissue Culture

Proceedings of the National Academy of Sciences - PNAS, 1991-12, Vol.88 (24), p.11241-11245

1991

Volltextzugriff (PDF)

Closely related NDM-1-encoding plasmids from Escherichia coli and Klebsiella pneumoniae in Taiwan

PloS one, 2014-08, Vol.9 (8), p.e104899-e104899

2014

Volltextzugriff (PDF)

Multiplex real-time PCR for detection of Staphylococcus aureus, mecA and Panton-Valentine Leukocidin (PVL) genes from selective enrichments from animals and retail meat

PloS one, 2014-05, Vol.9 (5), p.e97617

2014

Volltextzugriff (PDF)

1097P Long-term follow-up of advanced melanoma (unresectable/metastatic - aMel) patients (pts) treated with fianlimab (FIAN) + cemiplimab (CEMI): Results from blinded independent central review (BICR) efficacy assessment

Annals of oncology, 2024-09, Vol.35, p.S726-S727

2024

Volltextzugriff (PDF)

1384P Efficacy of cemiplimab as monotherapy or in combination with chemotherapy in Japanese patients with advanced non-small cell lung cancer (aNSCLC)

Annals of oncology, 2024-09, Vol.35, p.S868-S868

2024

Volltextzugriff (PDF)

A first insight into high prevalence of undiagnosed smear-negative pulmonary tuberculosis in Northern Ethiopian prisons: implications for greater investment and quality control

PloS one, 2014-09, Vol.9 (9), p.e106869-e106869

2014

Volltextzugriff (PDF)

790MO Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)

Annals of oncology, 2022-09, Vol.33, p.S905

2022

Volltextzugriff (PDF)

A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)

Annals of oncology, 2019-10, Vol.30, p.v560

2019

Volltextzugriff (PDF)

1 – 25 von 4.838

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.591)
Mit Volltextzugriff
(3.798)

Publikationsform

7 weitere anzeigen...

Weniger anzeigen...

Sprache

10 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.643)
Life Sciences & Biomedicine
(1.401)
Humans
(1.189)
Female
(597)
Animals
(594)
Male
(474)
Biological And Medical Sciences
(442)
Adult
(326)
Middle Aged
(286)
Mice
(282)
Medical Sciences
(280)
Oncology
(262)
Aged
(224)
Fundamental And Applied Biological Sciences. Psychology
(183)
Immunology
(174)
Microbiology
(171)
Social Sciences
(157)
Surgery
(155)
General & Internal Medicine
(154)
Infectious Diseases
(153)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Open access e-journals list
(2.138)
MEDLINE
(1.688)
Journals@Ovid
(1.288)
Publisher
(1.257)
Ingenta E-Journals
(1.215)
JSTOR
(955)
ScienceDirect
(551)
IngentaConnect Journals
(487)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(407)
Wiley Online Library All Journals
(375)
Springer journals
(311)
Ebook Central Perpetual and DDA
(283)
Wiley Online Library Full Collection 2018
(272)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(233)
eBooks on EBSCOhost
(229)
Sociological Abstracts
(219)
Taylor & Francis
(219)
Taylor & Francis Journals Collection
(191)
Oxford journals
(187)
Nexis Uni
(166)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(22)
... seit 30 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors

GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer

Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a phase I study

Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data

Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from phase I cohorts

Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)

CLINICAL ACTIVITY OF REGN1979, AN ANTI‐CD20 X ANTI‐CD3 BISPECIFIC ANTIBODY (AB) IN PATIENTS (PTS) WITH (W/) RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL)

Hormone replacement therapy, cancer, controversies, and women’s health: historical, epidemiological, biological, clinical, and advocacy perspectives

Risk factors for chronic and recurrent otitis media-a meta-analysis

Alarming proportions of methicillin-resistant Staphylococcus aureus (MRSA) in wound samples from companion animals, Germany 2010-2012

Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operons

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma

Epidemiology and prognostic factors of candidemia in cancer patients

Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma

Lavage with allicin in combination with vancomycin inhibits biofilm formation by Staphylococcus epidermidis in a rabbit model of prosthetic joint infection

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Human Immunodeficiency Virus Type 1 Mutants Resistant to Nonnucleoside Inhibitors of Reverse Transcriptase Arise in Tissue Culture

Closely related NDM-1-encoding plasmids from Escherichia coli and Klebsiella pneumoniae in Taiwan

Multiplex real-time PCR for detection of Staphylococcus aureus, mecA and Panton-Valentine Leukocidin (PVL) genes from selective enrichments from animals and retail meat

1097P Long-term follow-up of advanced melanoma (unresectable/metastatic - aMel) patients (pts) treated with fianlimab (FIAN) + cemiplimab (CEMI): Results from blinded independent central review (BICR) efficacy assessment

1384P Efficacy of cemiplimab as monotherapy or in combination with chemotherapy in Japanese patients with advanced non-small cell lung cancer (aNSCLC)

A first insight into high prevalence of undiagnosed smear-negative pulmonary tuberculosis in Northern Ethiopian prisons: implications for greater investment and quality control

790MO Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)

A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)

Suchergebnisse filtern